Ryght is an AI-driven platform revolutionizing clinical trial site selection and feasibility. The company uses generative AI to help sponsors and Contract Research Organizations (CROs) quickly find, select, and activate optimal research sites globally for their study protocols and continuously improve site performance throughout the trial.

In the rapidly evolving biopharma landscape, Ryght’s innovative technology addresses the inefficiencies of traditional site selection and feasibility methods. Through AI Site Twins, digital replicas of every clinical research site worldwide, Ryght captures unique operational characteristics, historical trial performance, and patient populations to provide predictive insights and optimize trial success.

Founded by experts with significant experience in AI, healthcare technology and clinical research, the Ryght team is committed to accelerating research, disease diagnosis, and trial matching using cutting-edge AI solutions.

- AI Site Twins technology creating dynamic data-derived replicas of every clinical research site worldwide.

- Advanced AI and machine learning for protocol analysis, site selection, feasibility assessments, and performance optimization.

- Cloud-based solutions available on Microsoft Azure Marketplace for scalable and cost-effective deployment.

- Strong industry partnerships with leading technology providers including Databricks, AWS, Microsoft Azure, Nvidia, and Hugging Face.

The company leadership includes CEO Simon Arkell, Chairman Alex Dickinson, Chief Medical Officer Chadi Nabhan, and other senior directors experienced in product development, AI engineering, business development, marketing, and customer success.

Ryght’s initial funding comes from leading ventures like Virtue, AIX Ventures, Iaso Ventures, Page One Ventures, Top Harvest Capital, and notable strategic angel investors. Their partner network blends robust security, cutting-edge technology, and infinite scalability to deliver AI-driven solutions tailored for life sciences.